[go: up one dir, main page]

MX2009004223A - Protocolo de inmunizacion contra los 4 serotipos del dengue. - Google Patents

Protocolo de inmunizacion contra los 4 serotipos del dengue.

Info

Publication number
MX2009004223A
MX2009004223A MX2009004223A MX2009004223A MX2009004223A MX 2009004223 A MX2009004223 A MX 2009004223A MX 2009004223 A MX2009004223 A MX 2009004223A MX 2009004223 A MX2009004223 A MX 2009004223A MX 2009004223 A MX2009004223 A MX 2009004223A
Authority
MX
Mexico
Prior art keywords
administration
immunization protocol
dengue
dengue serotypes
vaccine
Prior art date
Application number
MX2009004223A
Other languages
English (en)
Inventor
Bruno Guy
Veronique Barban
Remi Forrat
Jean Lang
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2009004223A publication Critical patent/MX2009004223A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención se relaciona a un método para inducir una protección contra los 4 serotipos del dengue en un paciente, que comprende: (a) la administración de una vacuna monovalente que comprende un virus de vacuna de un primer serotipo del dengue y (b) la administración de una vacuna tetravalente que comprende virus de vacuna de los cuatro serotipos del dengue, en donde la administración (b) se implementa por lo menos 30 días y a lo más 12 meses después de la primera administración (a).
MX2009004223A 2006-12-01 2007-11-30 Protocolo de inmunizacion contra los 4 serotipos del dengue. MX2009004223A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0655255A FR2909286B1 (fr) 2006-12-01 2006-12-01 Methode d'immunisation contre les 4 serotypes de la dengue
PCT/FR2007/052431 WO2008065315A1 (fr) 2006-12-01 2007-11-30 Methode d'immunisation contre les 4 serotypes de la dengue

Publications (1)

Publication Number Publication Date
MX2009004223A true MX2009004223A (es) 2009-04-30

Family

ID=38198298

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004223A MX2009004223A (es) 2006-12-01 2007-11-30 Protocolo de inmunizacion contra los 4 serotipos del dengue.

Country Status (16)

Country Link
US (2) US7718359B2 (es)
EP (1) EP2099483B1 (es)
JP (1) JP5269803B2 (es)
KR (1) KR20090087890A (es)
CN (1) CN101541344A (es)
AR (1) AR064009A1 (es)
AU (1) AU2007327367B2 (es)
BR (1) BRPI0718927A2 (es)
CA (1) CA2668570A1 (es)
FR (1) FR2909286B1 (es)
IL (2) IL198466A (es)
MX (1) MX2009004223A (es)
MY (1) MY180698A (es)
TW (1) TWI400249B (es)
WO (1) WO2008065315A1 (es)
ZA (1) ZA200902540B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0614265A2 (pt) * 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
NZ597000A (en) * 2009-06-01 2014-07-25 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
AU2010286368B2 (en) * 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
EP2877207A1 (en) 2012-07-24 2015-06-03 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US20150196631A1 (en) 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
WO2014083194A1 (en) 2012-11-30 2014-06-05 Sanofi Pasteur Methods for inducing antibodies
AU2014281713A1 (en) * 2013-06-21 2015-11-12 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
US10004795B2 (en) * 2015-09-08 2018-06-26 Fundacao Butantan Process for preparing an attenuated tetravalent dengue vaccine
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
BR112021003962A2 (pt) 2018-09-05 2021-05-25 Takeda Vaccines, Inc. dose unitária de vacina contra dengue e sua administração
BR112022001476A2 (pt) 2019-08-16 2023-10-03 Takeda Vaccines Inc Uso de uma vacina contra hepatite a e uma composição de vacina contra dengue ou uma dose unitária de uma composição de vacina contra dengue, combinação de vacina e kit
BR112022015710A2 (pt) 2020-02-27 2022-09-27 Takeda Vaccines Inc Método para remover dna de célula hospedeira a partir da preparação de vírus
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
EP4479025B1 (en) 2022-02-15 2026-02-04 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
CN120529951A (zh) 2022-11-29 2025-08-22 武田疫苗股份有限公司 大规模黄病毒疫苗生产和制造
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002516824A (ja) 1998-05-29 2002-06-11 エピミューン， インコーポレイテッド 広範に反応性のｄｒ拘束エピトープの同定
AU4040400A (en) 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
WO2000057907A2 (en) * 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
AU2001238441B2 (en) * 2000-02-16 2006-10-26 Mahidol University Avirulent, immunogenic flavivirus chimeras
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
US20040259224A1 (en) * 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
KR101199789B1 (ko) * 2003-03-24 2012-11-09 더 스크립스 리서치 인스티튜트 종양 성장 억제 ｄｎａ 백신
KR20080018271A (ko) * 2005-06-17 2008-02-27 사노피 파스퇴르 약독화된 뎅기 혈청형 2 균주
MX2007015873A (es) * 2005-06-17 2008-04-22 Sanofi Pasteur Cepa atenuada de virus de dengue serotipo 1.
BRPI0614265A2 (pt) * 2005-08-10 2011-03-22 Acambis Inc uso de uma vacina do vìrus da febre amarela e de uma vacina de flavivìrus quimérico e kit contendo referidas vacinas
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
AR061197A1 (es) * 2006-06-07 2008-08-13 Sanofi Pasteur Cepas del virus 3 del dengue vivas atenuadas
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.

Also Published As

Publication number Publication date
EP2099483A1 (fr) 2009-09-16
TW200829599A (en) 2008-07-16
FR2909286B1 (fr) 2012-06-08
JP5269803B2 (ja) 2013-08-21
US20100239612A1 (en) 2010-09-23
IL198466A0 (en) 2011-08-01
CA2668570A1 (en) 2008-06-05
IL230052A0 (en) 2014-01-30
US20080131460A1 (en) 2008-06-05
AU2007327367B2 (en) 2013-05-09
BRPI0718927A2 (pt) 2014-04-08
ZA200902540B (en) 2010-07-28
AU2007327367A1 (en) 2008-06-05
TWI400249B (zh) 2013-07-01
KR20090087890A (ko) 2009-08-18
WO2008065315A1 (fr) 2008-06-05
JP2010511022A (ja) 2010-04-08
FR2909286A1 (fr) 2008-06-06
CN101541344A (zh) 2009-09-23
AR064009A1 (es) 2009-03-04
MY180698A (en) 2020-12-07
IL198466A (en) 2014-01-30
EP2099483B1 (fr) 2013-12-25
US7718359B2 (en) 2010-05-18

Similar Documents

Publication Publication Date Title
MX2009004223A (es) Protocolo de inmunizacion contra los 4 serotipos del dengue.
MY169275A (en) Method of immunization against the four serotypes of dengue
MX2009003417A (es) Metodo de inmunizacion contra los 4 serotipos de dengue.
PH12021550479A1 (en) Dengue vaccine unit dose and administration thereof
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
WO2007124479A3 (en) Avian influenza viruses, vaccines, compositions, formulations, and methods
JP2010511022A5 (es)
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
EP1554301A4 (en) TETRAVALENT DENGUE VACCINE WITH A BLACK 30 NUCLEOTIDE DELETION IN 3'-UTR OF DENGUE TYPES 1,2,3 AND 4, OR ANTIGEN CHIMERAL DENGUE VIRUSES 1,2,3 AND 4
EP2491947A3 (en) Vaccine
WO2009060281A3 (en) Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties
MX2009006178A (es) Vacuna contra salmonela.
MY184428A (en) Compositions and methods for administration of vaccines against dengue virus
TN2011000182A1 (en) Live, attentuated respiratory syncytial virus
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
WO2007057763A3 (en) Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant
NZ591950A (en) Use of various antigens including antigens from mycoplasma bovis in multivalent vaccine composition
CA2915027A1 (en) Compositions and methods for administration of vaccines against dengue virus
PH12013501373B1 (en) Bovine viral diarrhea virus type 1b vaccine compositions and methods
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
WO2010012069A8 (en) Multivalent vaccines based on papaya mosaic virus and uses thereof
NO20075194L (no) vaksine
JP2009514840A5 (es)
NO20090290L (no) Polyvalent vaksine mot salmonid alfavirusinfeksjoner
WO2013012835A3 (en) Sirna useful in the treatment of flavivirus infection

Legal Events

Date Code Title Description
FG Grant or registration